EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis

Ahmad Diab iD, Henry Dickerson iD, Othman Al Musaimi iD

Pharmaceuticals · 09.01.2025 · 18 (1) · 70

DOI: 10.3390/ph18010070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 09.01.2025. Verfasst von Ahmad Diab und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic regimens. Currently, five approved drugs target cell wall biosynthesis in Mycobacterium tuberculosis. This review provides a comprehensive analysis of these drugs and their molecular mechanisms. Isoniazid, thioamides, and delamanid primarily disrupt mycolic acid synthesis, with recent evidence indicating that delamanid also inhibits decaprenylphosphoryl-β-D-ribose-2-epimerase, thereby impairing arabinogalactan biosynthesis. Cycloserine remains the sole approved drug that inhibits peptidoglycan synthesis, the foundational layer of the mycobacterial cell wall. Furthermore, ethambutol interferes with arabinogalactan synthesis by targeting arabinosyl transferase enzymes, particularly embB- and embC-encoded variants. Beyond these, six promising molecules currently in Phase II clinical trials are designed to target arabinan synthesis pathways, sutezolid, TBA 7371, OPC-167832, SQ109, and both benzothiazinone derivatives BTZ043 and PBTZ169, highlighting advancements in the development of cell wall-targeting therapies.

Schlagwörter

Stichwörter der Autor:innen

arabinogalactanclinical trialscycloserinedelamanidisoniazidmulti-drug resistancemycobacterium tuberculosismycolic acidpeptidoglycan

Autor:innen und Institutionen

  • School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
  • Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.

ORCID-Profile: Ahmad Diab, Henry Dickerson, Othman Al Musaimi

Zitieren

APA

Diab, A., Dickerson, H., & Al Musaimi, O. (2025). Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis. Pharmaceuticals, 18(1), 70. https://doi.org/10.3390/ph18010070

Vancouver

Diab A, Dickerson H, Al Musaimi O. Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis. Pharmaceuticals. 2025;18(1):70. doi:10.3390/ph18010070

BibTeX
@article{Diab2025,
  author = {Diab, Ahmad and Dickerson, Henry and Al Musaimi, Othman},
  title = {Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {70},
  doi = {10.3390/ph18010070}
}
Kostenlos starten →